Literature DB >> 24249045

Alzheimer's as a metabolic disease.

Lloyd A Demetrius1, Jane Driver.   

Abstract

Empirical evidence indicates that impaired mitochondrial energy metabolism is the defining characteristic of almost all cases of Alzheimer's disease (AD). Evidence is reviewed supporting the general hypothesis that the up-regulation of OxPhos activity, a metabolic response to mitochondrial dysregulation, drives the cascade of events leading to AD. This mode of metabolic alteration, called the Inverse Warburg effect, is postulated as an essential compensatory mechanism of energy production to maintain the viability of impaired neuronal cells. This article appeals to the inverse comorbidity of cancer and AD to show that the amyloid hypothesis, a genetic and neuron-centric model of the origin of sporadic forms of AD, is not consistent with epidemiological data concerning the age-incidence rates of AD. A view of Alzheimer's as a metabolic disease-a condition consistent with mitochondrial dysregulation and the Inverse Warburg effect, will entail a radically new approach to diagnostic and therapeutic strategies.

Entities:  

Mesh:

Year:  2013        PMID: 24249045     DOI: 10.1007/s10522-013-9479-7

Source DB:  PubMed          Journal:  Biogerontology        ISSN: 1389-5729            Impact factor:   4.277


  38 in total

1.  Shared genetic architecture between metabolic traits and Alzheimer's disease: a large-scale genome-wide cross-trait analysis.

Authors:  Zhaozhong Zhu; Yifei Lin; Xihao Li; Jane A Driver; Liming Liang
Journal:  Hum Genet       Date:  2019-02-25       Impact factor: 4.132

2.  Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.

Authors:  Ariela R Orkaby; Kelly Cho; Jean Cormack; David R Gagnon; Jane A Driver
Journal:  Neurology       Date:  2017-09-27       Impact factor: 9.910

3.  Multi-omics Evidence for Inheritance of Energy Pathways in Red Blood Cells.

Authors:  Erin M M Weisenhorn; Thomas J van T Erve; Nicholas M Riley; John R Hess; Thomas J Raife; Joshua J Coon
Journal:  Mol Cell Proteomics       Date:  2016-10-24       Impact factor: 5.911

4.  Bioenergetic mechanisms in astrocytes may contribute to amyloid plaque deposition and toxicity.

Authors:  Wen Fu; Diya Shi; David Westaway; Jack H Jhamandas
Journal:  J Biol Chem       Date:  2015-03-26       Impact factor: 5.157

Review 5.  Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.

Authors:  Jane A Driver; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Biochim Biophys Acta       Date:  2015-01-10

Review 6.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

7.  Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease.

Authors:  Sheng Wang; Feng Yang; Vladislav A Petyuk; Anil K Shukla; Matthew E Monroe; Marina A Gritsenko; Karin D Rodland; Richard D Smith; Wei-Jun Qian; Cheng-Xin Gong; Tao Liu
Journal:  J Pathol       Date:  2017-07-28       Impact factor: 7.996

Review 8.  Preventing Alzheimer's disease by means of natural selection.

Authors:  Lloyd A Demetrius; Jane A Driver
Journal:  J R Soc Interface       Date:  2015-01-06       Impact factor: 4.118

9.  Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles.

Authors:  Kai-C Sonntag; Woo-In Ryu; Kristopher M Amirault; Ryan A Healy; Arthur J Siegel; Donna L McPhie; Brent Forester; Bruce M Cohen
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

10.  Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice.

Authors:  Miren Ettcheto; Amanda Cano; Patricia R Manzine; Oriol Busquets; Ester Verdaguer; Rubén Dario Castro-Torres; Maria Luisa García; Carlos Beas-Zarate; Jordi Olloquequi; Carme Auladell; Jaume Folch; Antoni Camins
Journal:  Mol Neurobiol       Date:  2019-12-14       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.